Tang L, Sorajja P, Mooney M, et al. - Using the Allina Health System, researchers determined long‐term results among patients experiencing severe comorbidities (sCM) and undergoing transcatheter aortic valve replacement (TAVR) (n = 890, 82 ± 8 years, 55% men). Severe lung disease, severe liver disease, end‐stage renal disease, severe, severe dementia, severe dilated cardiomyopathy, and frailty, all constituted sCM. Experts compared patients with (n = 215, 24%) and without (n = 675, 76%) sCM in terms of outcomes. A lower 3‐year survival free from all‐cause death, and lower 3‐year survival free from the composite endpoint of all‐cause death, re‐hospitalization for heart failure, myocardial infarction or stroke, was observed in patients with sCM vs those without sCM. Overall, findings revealed poor 3‐year outcomes in TAVR patients with sCM but these patients may have improvements in their quality of life.